Literature DB >> 17473184

The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.

Rui Yang1, E Anders Kolb, Jing Qin, Alexander Chou, Rebecca Sowers, Bang Hoang, John H Healey, Andrew G Huvos, Paul A Meyers, Richard Gorlick.   

Abstract

PURPOSE: Two major systems exist for folate cell entry: the reduced folate carrier (RFC) and the folate receptor (FR). Although defective RFC-mediated transport was frequently identified as a mechanism of methotrexate (MTX) resistance in osteosarcoma, the status of FR and its role in this disease are unknown. EXPERIMENTAL
DESIGN: mRNA for FR alpha was measured in 107 osteosarcoma specimens using quantitative reverse transcription-PCR and was related to RFC expression. The effect of FR alpha overexpression on MTX resistance and natural folate uptake was studied using FR alpha non-expressing osteosarcoma 143B cells transfected with FR alpha cDNA in comparison with those transfected with sense or antisense RFC in the same genetic background.
RESULTS: Eighty-four samples (78.5%) had detectable FR alpha mRNA, and 29.9% had higher levels than the ovarian cancer cell line SKOV-3. No correlation was found between mRNA levels of FR alpha and RFC (r(2)=0.002). FR alpha overexpression had minor effects on the transport of MTX and sensitivity to this drug. Among the transfected 143B sublines, only the 143B-FR alpha was able to uptake 5-methyltetrahydrofolate when the extracellular concentration was reduced to 2 nmol/L, which conferred a growth advantage in physiologic folate concentrations compared with vector-only-transfected cells. Importantly, this was not similarly achieved by RFC overexpression.
CONCLUSIONS: This study suggests that FR alpha plays a role in the uptake of 5-methyltetrahydrofolate when the concentration gradient is insufficient for RFC-mediated transport. FR alpha overexpression is unlikely secondary to the decreased RFC expression in osteosarcoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473184     DOI: 10.1158/1078-0432.CCR-06-1343

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  18 in total

1.  The combined effect of encapsulating curcumin and C6 ceramide in liposomal nanoparticles against osteosarcoma.

Authors:  Santosh S Dhule; Patrice Penfornis; Jibao He; Michael R Harris; Treniece Terry; Vijay John; Radhika Pochampally
Journal:  Mol Pharm       Date:  2014-01-24       Impact factor: 4.939

2.  Utilization of targeted near-infrared molecular imaging to improve pulmonary metastasectomy of osteosarcomas.

Authors:  Jarrod D Predina; Andrew Newton; Charuhas Deshpande; Philip Low; Sunil Singhal
Journal:  J Biomed Opt       Date:  2018-01       Impact factor: 3.170

Review 3.  Intraoperative fluorescence imaging in thoracic surgery.

Authors:  Andrew D Newton; Jarrod D Predina; Shuming Nie; Philip S Low; Sunil Singhal
Journal:  J Surg Oncol       Date:  2018-08-11       Impact factor: 3.454

4.  PBPK modeling-based optimization of site-specific chemo-photodynamic therapy with far-red light-activatable paclitaxel prodrug.

Authors:  Mengjie Li; Luong Nguyen; Bharathiraja Subramaniyan; Moses Bio; Cody J Peer; Jessica Kindrick; William D Figg; Sukyung Woo; Youngjae You
Journal:  J Control Release       Date:  2019-07-09       Impact factor: 9.776

5.  Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.

Authors:  F Leung; A Dimitromanolakis; H Kobayashi; E P Diamandis; V Kulasingam
Journal:  Clin Biochem       Date:  2013-03-23       Impact factor: 3.281

6.  MR imaging of ovarian tumors using folate-receptor-targeted contrast agents.

Authors:  Zhen J Wang; Sophie Boddington; Michael Wendland; Reinhard Meier; Claire Corot; Heike Daldrup-Link
Journal:  Pediatr Radiol       Date:  2008-03-21

Review 7.  Translational biology of osteosarcoma.

Authors:  Maya Kansara; Michele W Teng; Mark J Smyth; David M Thomas
Journal:  Nat Rev Cancer       Date:  2014-10-16       Impact factor: 60.716

8.  Polymorphisms and methylation of the reduced folate carrier in osteosarcoma.

Authors:  Rui Yang; Jing Qin; Bang H Hoang; John H Healey; Richard Gorlick
Journal:  Clin Orthop Relat Res       Date:  2008-06-05       Impact factor: 4.176

Review 9.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

10.  Functional folate receptor alpha is elevated in the blood of ovarian cancer patients.

Authors:  Eati Basal; Guiti Z Eghbali-Fatourechi; Kimberly R Kalli; Lynn C Hartmann; Karin M Goodman; Ellen L Goode; Barton A Kamen; Philip S Low; Keith L Knutson
Journal:  PLoS One       Date:  2009-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.